Drugs / Bifidobacterium breve
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06793514 | Feb → May 2025 overdue | dry eye syndrome | Mohsen Pourazizi | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00737841 | Jan 2006 → Aug 2008 | irritable bowel syndrome | Tohoku University | Unknown | No outcome recorded |
| — | NCT00464867 | Jan 2006 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02244047 Comparator | Oct 2013 → Jun 2014 | celiac disease | University Medical Centre Maribor | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium breve | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗3“In the present proposal we would like to examine if supplementation with the probiotic Bifidobacterium breve has a beneficial role in enhancing the immunogenicity of Dukoral in...” NCT00464867 ↗ |
| Modality | Other / unclassified | “the probiotic Bifidobacterium breve” NCT00464867 ↗ |
| Route | Oral | “taking orally” NCT00737841 ↗ |